Japanese Pharmacopoeia - Draft Chapter of alternative Endotoxin Testing
The Japanese Pharnacopoe has published a new chapter draft of "Bacterial Endotoxins Test and alternative methods using recombinant protein-reagents for endotoxin assay" for comment.
Evaluation of the Immunogenicity of Therapeutic Protein Products - FDA Scientists developed a new Tool
For the important assessment of possible immune responses to therapeutic protein drugs, FDA scientists developed a new mathematical tool to calculate the expected risk of producing antibodies against the biological drug.
FDA publishes Q&A on Internal Standard Responses in Chromatography Bioanalysis
In support of sponsors, applicants and research institutions, the FDA examines in more detail the variability of internal standards in analytics and their consequences. The authority has now published a document entitled "Evaluation of Internal Standard Responses During Chromatographic Bioanalysis: Questions and Answers".
ATMP from Third Countries - New Q&A Paper on Batch Release published
With a new Q&A document, the EMA has provided information on the release of Adavanved Therapy Medicinal Products (ATMP) imported into the EU by the Qualified Person without batch re-testing.
FDA's promotion for cell and tissue products - the TRG Rapid Inquiry Program (TRIP)
With an additional program to support manufacturers of cells, tissues and cell-based products, the FDA is trying to accelerate its promotion of the development of regenerative therapies.
Do liquid, sterile medicinal products have to be particle-free?
According to the pharmacopoeias, parenteralia, i.e. sterile medicinal products for injection purposes, must be 100% visually inspected. In addition to damages to the primary container, the absence of particles has also to be checked. But do these medicinal products also have to be 100% free of particles? Read more here.
FDA keeps an eye on use and marketing of cell and tissue products
The FDA publishes an Untitled Letter to a manufacturer of stem cell products that are used to treat various diseases and are not expected to meet regulatory requirements.
ATMPs in combination with a medical device - QP task on release
With the coming into force of the Advanced Therapy Medicinal Products (ATMPs) GMP rules as Part IV of the EU GMP Guidelines, a new chapter has been opened on the manufacture and quality control of ATMPs. Special requirements are placed on the QP when an ATMP is combined with a medical device.
How to handle possibly lifesaving OOS batches of ATMP - A question that concerns manufacturers and authorities
In the context of a Q&A document, the European Medicines Agency (EMA) offers assistance and information on when an Advanced Therapy Medicinal Product (ATMP) can be approved for treatment even in the case of an out-of-specification batch.
Transmission of multiresistant microorganisms during transplantation
Following incidents involving the transmission of multi-resistant germs during the use of faecel microorganisms for transplantation, the FDA has established additional measures to minimise the risk of transmission.
FDA issues Warning Letter to Manufacturer of Human Cells, Tissue or Cell based Products
The FDA has published a Warning Letter to a manufacturer of umbilical cord blood products for therapeutic use in humans due to deficiencies in the classification and manufacture of the products.
Updated Information about the Risk of ZIKA Virus Transmission via Cells and Tissues
Based on the updated information from the CDC, the FDA pointed out the current risk assessment for the transmission of Zika virus through blood, cell or tissue products at the end of February.
Monographs on Vaccines and Immunosera - Revised Expert Guidance
During its 162th session, the European Pharmacopoeia Commission published the revised guideline "Guide for the elaboration and use of monographs on vaccines and immunosera for human use", which helps experts and interested parties in this field to prepare and interpret the monographs.